Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00276835 · ClinicalTrials.gov registry record · Early Phase 1
Genistein and Interleukin-2 in Treating Patients With Metastatic Melanoma or Kidney Cancer
A Early Phase 1 study of Kidney Cancer and Melanoma (Skin), sponsored by Northwestern University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT00276835: Completed Early Phase 1 study of Kidney Cancer and Melanoma (Skin), sponsored by Northwestern University.
NCT00276835 is a Early Phase 1 study of Kidney Cancer and Melanoma (Skin) that has completed, run by Northwestern University. The registered enrollment target is 15 participants, below the 880-participant average among 60 other Kidney Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00276835, a Early Phase 1 study of Kidney Cancer and Melanoma (Skin), has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Genistein may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Interleukin-2 may stimulate the white blood cells, including natural killer cells, to kill melanoma or kidney cancer cells. Giving genistein together with interleukin-2 may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving genistein together with interleukin-2 works in treating patients with metastatic melanoma or kidney cancer.
Conditions Studied
Interventions
- BIOLOGICAL High-dose interleukin-2
- DIETARY_SUPPLEMENT genistein
Study Locations (1)
Illinois
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2005-11 |
| Est. Completion | 2014-01 |
| Phase | Early Phase 1 |
What the finished NCT00276835 record still lists
NCT00276835 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 880-participant average among 60 other Kidney Cancer trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Kidney Cancer appearing as the primary indexed condition, and to 2 interventions - of which High-dose interleukin-2 is the first listed.
NCT00276835 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT00276835 about?
NCT00276835 is a clinical study titled "Genistein and Interleukin-2 in Treating Patients With Metastatic Melanoma or Kidney Cancer". RATIONALE: Genistein may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Interleukin-2 may stimulate the white blood cells, including natural killer cells, to kill melanoma or kidney cancer cells. Giving genistein togethe...
What is the current status of trial NCT00276835?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 15 participants. The study started on 2005-11. Estimated completion is 2014-01.
What conditions does trial NCT00276835 study?
This clinical trial studies the following conditions: Kidney Cancer, Melanoma (Skin).
What interventions are being tested in trial NCT00276835?
The interventions under investigation include: High-dose interleukin-2 (BIOLOGICAL), genistein (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00276835?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00276835 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00276835's enrollment target sits among peer trials
15 55th of 60 higher than 5 of 60 other Kidney Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kidney Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Patient Navigation Program to Improve Clinical Trial Enrollment in Cancer Patients
RECRUITING · NA
-
Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform
RECRUITING
-
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
RECRUITING
-
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders
RECRUITING
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
-
Genetic Analysis of Birt Hogg-Dube Syndrome and Characterization of Predisposition to Kidney Cancer
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia